Cardiovascular Protective Properties of GLP-1 Receptor Agonists: More than Just Diabetic and Weight Loss Drugs
Open accessThe DOI matches its Crossref record; 177 of the 178 references it cites were found in a registry or an index.
Abstract
Owing to their potent glucose-lowering efficacy and substantial weight loss effects, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are now considered part of the frontline therapeutic options to treat both type 2 diabetes mellitus and nondiabetic overweight/obesity. Stemming from successful demonstration of their cardiometabolic modulation and reduction of major adverse cardiovascular events in clinical outcome trials, GLP-1 RAs have since been validated as agents with compelling cardiovascular protective properties. Studies spanning from the bench to preclinical and large-scale randomised controlled trials have consistently corroborated the cardiovascular benefits of this pharmacological class. Most notably, there is converging evidence that they exert favourable effects on atherosclerotic ischaemic endpoints, with preclinical data indicating that they may do so by directly modifying the burden and composition of atherosclerotic plaques. This narrative review examines the underlying pharmacology and clinical evidence behind the cardiovascular benefits of GLP-1 RAs, with particular focus on atherosclerotic cardiovascular disease. It also delves into the mechanisms that underpin their putative plaque-modifying actions, addresses existing knowledge gaps and therapeutic challenges and looks to future developments in the field, including the use of combination incretin agents for diabetes and weight loss management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Cardiovascular outcome trials confirm reductions in major adverse cardiovascular events, and emerging evidence suggests benefits for renal function and inflammation (8, 24–29).”
From GLP-1 agonists and exercise: the future of lifestyle prioritization (2025) · cites this paper as [29]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019
Roth, G. A., Mensah, G. A., Johnson, C. O., Addolorato, G., Ammirati, E., Baddour, L. M., Barengo, N. C., Beaton, A. Z., Benjamin, E. J., Benziger, C. P., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.010 · Cited by 11,449 · cited 1×
“In 2019, it was estimated that of 523 million people affected by all-cause CVD worldwide, there were 197 million prevalent cases of coronary artery disease (CAD), resulting in 9 million deaths [2].”
BackgroundSaeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., Colagiuri, S., Guariguata, L., Motala, A. A., Ogurtsova, K., et al. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107843 · Cited by 10,792 · cited 1×
“T2DM currently affects 463 million people globally, a number predicted to increase by 25% in 2030 and 51% in 2045 [4].”
Background(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 4×
“Moreover, several have also achieved significant reductions compared to placebo in composite MACEs, usually comprising the endpoints of cardiovascular death, nonfatal myocardial infarction (MI) and nonfatal ischaemic stroke [50,54,56,57,59] (Table 2).”
BackgroundInfluentialIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397 · cited 1×
“While better glycaemic control has long been associated with improved microvascular complications of T2DM, it has been more difficult to demonstrate this relationship for ASCVD (or macrovascular) outcomes [85].”
BackgroundSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 10×
“For example, in SUSTAIN-6 64% of participants were also taking aspirin, 21% clopidogrel or ticagrelor, 77% lipid-lowering medication (mostly statins) and 94% anti-hypertensives with 50% on ACE inhibitors [50].”
BackgroundMethodInfluentialEvolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138 · cited 1×
“These include PCSK9 inhibitors (e.g., evolocumab [65]) and anti-inflammatory agents, such as colchicine [66].”
BackgroundOnce-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 1×
“For patients with overweight or obesity who did not have T2DM, 2.4 mg of semaglutide in the STEP1 trial led to mean bodyweight reduction of 14.9% (2.4% with placebo), with 86% and 51% of participants achieving ≥ 5% and ≥ 15% bodyweight reductions, respectively [94].”
BackgroundInfluentialCosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 1×
“Tirzepatide, a novel ‘twincretin’ targeting both GLP-1 and GIP receptors, has demonstrated efficacy for treating T2DM in the SURPASS clinical trial program [168] and overweight/obesity in the SURMOUNT studies [169].”
BackgroundDavies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236 · cited 5×
“Similarly, as we learn more about how GLP-1 RAs protect against atherosclerosis and CVD with trials such as SELECT [91], we will need to consider how management of ASCVD with these agents fits within this wider issue of equitable access and the effects of withdrawal of treatments, which can result…”
BackgroundInfluentialGerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163 · cited 6×
“Moreover, several have also achieved significant reductions compared to placebo in composite MACEs, usually comprising the endpoints of cardiovascular death, nonfatal myocardial infarction (MI) and nonfatal ischaemic stroke [50,54,56,57,59] (Table 2).”
BackgroundInfluentialEfficacy and safety of low-dose colchicine after myocardial infarction
Tardif, J.-C., Kouz, S., Waters, D. D., Bertrand, O. F., Diaz, R., Maggioni, A. P., Pinto, F. J., Ibrahim, R., Gamra, H., Kiwan, G. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1912388 · Cited by 3,159 · cited 1×
“These include PCSK9 inhibitors (e.g., evolocumab [65]) and anti-inflammatory agents, such as colchicine [66].”
BackgroundCardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
The changing landscape of atherosclerosis
Libby, P. (2021) · Nature · doi:10.1038/s41586-021-03392-8 · Cited by 2,873 · cited 1×
“As the leading cause of morbidity and mortality, cardiovascular disease (CVD) represents a formidable global disease burden [1].”
BackgroundCollaborators, C. T. T. (. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60367-5 · Cited by 2,833 · cited 1×
“Meanwhile, statins are recognised to reduce major vascular events by ~21% for every 1.0 mmol/L reduction in LDL-C [63], which is similar to the overall benefit from the ACE inhibitor, ramipril, in the HOPE study where almost 40% of participants had diabetes [64].”
MethodInfluentialLixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409 · cited 6×
“…outcome trials, which have been FDA-mandated since 2008 to identify potential adverse cardiovascular events caused by new anti-diabetic agents [50,53–59], have highlighted beneficial cardiovascular properties of GLP-1 RAs, albeit with some heterogeneity between different agents (Table 2).”
BackgroundResultInfluentialMechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170 · cited 2×
“…tracts, GLP-1R Although predominantly found in the gastrointestinal and neural tracts, GLP-1R is also present in other tissues, including kidney, skeletal and smooth muscle, liver and adipose [39]. also present in other tissues, including kidney, skeletal and smooth muscle, liver and adipose [39].”
BackgroundEffects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., Chan, J. C., Choi, J., Gustavson, S. M., Iqbal, N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612917 · Cited by 2,162 · cited 3×
“Other trials reported statistically, but not clinically, significant improvements in LDL-C levels [55,57,59].”
BackgroundResultEffects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2403347 · Cited by 2,099 · cited 1×
“Recent trial evidence also suggests a beneficial effect of GLP-1 RA use on diabetic renal disease [167], which supports signals observed in the early GLP-1 trials [9].”
BackgroundTirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096 · cited 1×
“Tirzepatide, a novel ‘twincretin’ targeting both GLP-1 and GIP receptors, has demonstrated efficacy for treating T2DM in the SURPASS clinical trial program [168] and overweight/obesity in the SURMOUNT studies [169].”
BackgroundOral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997 · cited 3×
“In contrast, the studies for exenatide, lisixe-natide and oral semaglutide did not reach statistical significance for superiority compared to placebo [53,55,58].”
BackgroundResultGlucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928 · cited 1×
“The incretin effect was attributed to incretin hormones, particularly glucagon-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) [14,15].”
BackgroundGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Hernandez, A. F., Green, J. B., Janmohamed, S., D'Agostino, R. B., Granger, C. B., Jones, N. P., Leiter, L. A., Rosenberg, A. E., Sigmon, K. N., Somerville, M. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32261-x · Cited by 1,829 · cited 5×
“Moreover, in the AMPLITUDE-O, HARMONY OUTCOMES and SUSTAIN-6 trials [50,56,59], there were significant reductions in the expanded composite outcome, defined as hospitalisations for unstable angina and urgent coronary revascularisations.”
BackgroundMethodInfluentialWing, R. R., Lang, W., Wadden, T. A., Safford, M., Knowler, W. C., Bertoni, A. G., Hill, J. O., Brancati, F. L., Peters, A., Wagenknecht, L., et al. (2011) · Diabetes Care · doi:10.2337/dc10-2415 · Cited by 1,828 · cited 1×
“Weight loss can favourably modify cardiometabolic risk factors [89] and reverse the chronic inflammation of an obesogenic microenvironment [90].”
BackgroundImmunity and Inflammation in Atherosclerosis
Wolf, D., & Ley, K. (2019) · Circulation Research · doi:10.1161/circresaha.118.313591 · Cited by 1,697 · cited 1×
“Coronary artery disease, alongside peripheral artery disease (PAD) and ischaemic strokes, is a manifestation of atherosclerosis, a process whereby arteries undergo gradual stiffening and stenosis due to the build-up of inflammatory, fibro-lipidic plaques in their subintimal compartment [3].”
BackgroundSemaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306963 · Cited by 1,669 · cited 3×
“Furthermore, there were also reductions in systolic blood pressure (BP), C-reactive protein (CRP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) [72].”
BackgroundInfluentialSattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S., Lam, C. S. P., Lopes, R. D., McMurray, J. J. V., Pratley, R. E., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00203-5 · Cited by 1,599 · cited 6×
“Recent trial evidence also suggests a beneficial effect of GLP-1 RA use on diabetic renal disease [167], which supports signals observed in the early GLP-1 trials [9].”
BackgroundInfluentialBuse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetes Care · doi:10.2337/dci19-0066 · Cited by 1,192 · cited 1×
“…guideline-recommended by the European Society for Cardiology, American Diabetes Association and European Association for the Study of Diabetes in patients with T2DM and concurrent ASCVD or at high risk of ASCVD, such as those with target organ damage or multiple cardiovascular risk factors [82,83].”
BackgroundWilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., Lingvay, I., McGowan, B. M., Oral, T. K., Rosenstock, J., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14725 · Cited by 1,128 · cited 1×
“…atherosclerosis and CVD with trials such as SELECT [91], we will need to consider how management of ASCVD with these agents fits within this wider issue of equitable access and the effects of withdrawal of treatments, which can result in weight regain and reversal of cardiometabolic benefits [164].”
BackgroundBan, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · cited 2×
“[115].”
BackgroundThe arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961 · cited 2×
“…[36]. activate neurons containing pro-opiomelanocortin/cocaine-and amphetamine-stimulated transcription (POMC + /CART + ), resulting in satiety [35 can concurrently stimulate local inhibitory GABA neurons, which indirectly It is thought that vagal innervation is involved in the GLP-1…”
BackgroundIncretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950 · cited 3×
“GIP and GLP-1 are secreted from special entero-endocrine ‘K’ and ‘L’ cells, respectively, which are located predominantly in the small intestine and the colon [16].”
BackgroundKhera, R., Murad, M. H., Chandar, A. K., Dulai, P. S., Wang, Z., Prokop, L. J., Loomba, R., Camilleri, M., & Singh, S. (2016) · JAMA · doi:10.1001/jama.2016.7602 · Cited by 865 · cited 1×
“Although GLP-1 RAs are one of the most effective agents within the existing pharmacological armamentarium for obesity [93], the degree of weight loss varies between different agents (Table 2).”
BackgroundSTIMULATION OF INSULIN SECRETION BY GASTRIC INHIBITORY POLYPEPTIDE IN MAN. 1
Dupre, J., Ross, S. A., Watson, D., & Brown, J. C. (1973) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-37-5-826 · Cited by 860 · cited 1×
“The incretin effect was attributed to incretin hormones, particularly glucagon-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) [14,15].”
BackgroundPlasma Insulin Response to Oral and Intravenous Glucose Administration1
ELRICK, H., STIMMLER, L., HLAD, C. J., & ARAI, Y. (1964) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-24-10-1076 · Cited by 857 · cited 1×
“In 1964, it was found that orally administered glucose elicits a significantly greater insulin response than parenterally administered glucose [11,12].”
BackgroundCardiovascular and renal outcomes with efpeglenatide in type 2 diabetes
Gerstein, H. C., Sattar, N., Rosenstock, J., Ramasundarahettige, C., Pratley, R., Lopes, R. D., Lam, C. S. P., Khurmi, N. S., Heenan, L., Del Prato, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108269 · Cited by 829 · cited 8×
“Moreover, in the AMPLITUDE-O, HARMONY OUTCOMES and SUSTAIN-6 trials [50,56,59], there were significant reductions in the expanded composite outcome, defined as hospitalisations for unstable angina and urgent coronary revascularisations.”
BackgroundMethodInfluentialZelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Furtado, R. H. M., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.038868 · Cited by 781 · cited 1×
“As a class, GLP-1 RAs do not reduce heart failure hospitalisations to the same extent as SGLT2 inhibitors, which can reduce heart-failure-related hospitalisations by ~30% [71].”
BackgroundNew Interpretation of Oral Glucose Tolerance
Mcintyre, N., Holdsworth, C. D., & Turner, D. S. (1964) · The Lancet · doi:10.1016/s0140-6736(64)90011-x · Cited by 738 · cited 1×
“In 1964, it was found that orally administered glucose elicits a significantly greater insulin response than parenterally administered glucose [11,12].”
Background(2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30162-0 · Cited by 738
The Cardiovascular Biology of Glucagon-like Peptide-1
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.009 · Cited by 665 · cited 1×
“…on cardiomyocytes and Within the cardiovascular system, it is expressed on cardiomyocytes and vascular smooth muscle and endothelial cells [39], along with circulating inflammatory cells [40]. vascular smooth muscle and endothelial cells [39], along with circulating in fl ammatory cells [40].”
BackgroundFuster, J. J., Ouchi, N., Gokce, N., & Walsh, K. (2016) · Circulation Research · doi:10.1161/circresaha.115.306885 · Cited by 664 · cited 1×
“Weight loss can favourably modify cardiometabolic risk factors [89] and reverse the chronic inflammation of an obesogenic microenvironment [90].”
BackgroundNauck, M. A., Heimesaat, M. M., Behle, K., Holst, J. J., Nauck, M. S., Ritzel, R., Hüfner, M., & Schmiegel, W. H. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8355 · Cited by 605 · cited 1×
“As the insulinotropic effects are glucose-dependent and the counterregulatory response of glucagon to hypoglycaemia remains intact with GLP-1 infusion [19], the risk of hypoglycaemia is low.”
BackgroundFilippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560 · cited 1×
“The key adverse effects associated with GLP-1 RAs are gastrointestinal, such as nausea, vomiting, abdominal pain and diarrhoea [47].”
BackgroundRakipovski, G., Rolin, B., Nøhr, J., Klewe, I., Frederiksen, K. S., Augustin, R., Hecksher-Sørensen, J., Ingvorsen, C., Polex-Wolf, J., & Knudsen, L. B. (2018) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2018.09.004 · Cited by 509 · cited 3×
“In another study, semaglutide reduced the plaque content of CD163 + macrophages [108], which is associated with decreased intraplaque angiogenesis and a lower risk of plaque haemorrhage and rupture [108,157].”
BackgroundNauck, M. A., & Meier, J. J. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00482-9 · Cited by 503 · cited 1×
“This phenomenon of exaggerated or amplified insulin response to oral glucose is now known as the ‘incretin effect’ and is substantially reduced in T2DM [13].”
BackgroundDaily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
Wharton, S., Blevins, T., Connery, L., Rosenstock, J., Raha, S., Liu, R., Ma, X., Mather, K. J., Haupt, A., Robins, D., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2302392 · Cited by 478 · cited 1×
“Early trials have found benefits for both obesity [172] and diabetes [173], expanding oral GLP-1 RA choices.”
BackgroundYusta, B., Baggio, L. L., Estall, J. L., Koehler, J. A., Holland, D. P., Li, H., Pipeleers, D., Ling, Z., & Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.10.001 · Cited by 446 · cited 1×
“GLP-1R activation further reduces endoplasmic reticular (ER) stress in β cells, preserving cellular function despite the cellular stresses induced by increased insulin biosynthesis [30] (Figure 1).”
BackgroundGLP-1 Receptor Activation Modulates Appetite- and Reward-Related Brain Areas in Humans
van Bloemendaal, L., IJzerman, R. G., ten Kulve, J. S., Barkhof, F., Konrad, R. J., Drent, M. L., Veltman, D. J., & Diamant, M. (2014) · Diabetes · doi:10.2337/db14-0849 · Cited by 427 · cited 2×
“There is also evidence that GLP-1 RAs can attenuate hyperstimulation of neural appetite and reward centres (insula, amygdala, putamen and orbitofrontal cortex) through direct GLP-1R agonism [38].”
BackgroundRosenstock, J., Frias, J., Jastreboff, A. M., Du, Y., Lou, J., Gurbuz, S., Thomas, M. K., Hartman, M. L., Haupt, A., Milicevic, Z., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01053-x · Cited by 423 · cited 1×
“Additionally, within the incretin drug pipeline, retatrutide, a unimolecular peptide with tri-agonist activity at the GIP, GLP-1 and glucagon receptors, recently showed promising results in a phase 2 evaluation for both weight loss and glycaemic control [171].”
BackgroundPharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
Tahrani, A. A., Barnett, A. H., & Bailey, C. J. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.86 · Cited by 398
Adiponectin, Leptin and Cardiovascular Disorders
Zhao, S., Kusminski, C. M., & Scherer, P. E. (2021) · Circulation Research · doi:10.1161/circresaha.120.314458 · Cited by 373 · cited 1×
“In fact, low serum adiponectin levels may be an independent predictor for future ASCVD events and a marker of CAD severity [146].”
BackgroundLong-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
Ryan, D. H., Lingvay, I., Deanfield, J., Kahn, S. E., Barros, E., Burguera, B., Colhoun, H. M., Cercato, C., Dicker, D., Horn, D. B., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02996-7 · Cited by 347 · cited 1×
“This is in addition to post hoc analysis showing that weight loss was sustained in this cohort for up to four years [102].”
ResultTsapas, A., Avgerinos, I., Karagiannis, T., Malandris, K., Manolopoulos, A., Andreadis, P., Liakos, A., Matthews, D. R., & Bekiari, E. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0864 · Cited by 346 · cited 2×
“Notably, whereas SGLT2 inhibitors reduced heart failure hospitalisation, semaglutide and dulaglutide were associated with lower risk of stroke [61].”
BackgroundTirzepatide cardiovascular event risk assessment: A pre-specified meta-analysis
Sattar, N., McGuire, D. K., Pavo, I., Weerakkody, G. J., Nishiyama, H., Wiese, R. J., & Zoungas, S. (2022) · Nature Medicine · doi:10.1038/s41591-022-01707-4 · Cited by 346 · cited 1×
“Although the cardiovascular safety of tirzepatide has been established in short-term trials [170], proof of beneficial effects on hard cardiovascular outcomes is still awaited with dedicated outcome trials ongoing (SURPASS-CVOT, NCT04255433; SURMOUNT-MMO, NCT05556512) (Table 3).”
BackgroundPolypill strategy in secondary cardiovascular prevention
Castellano, J. M., Pocock, S. J., Bhatt, D. L., Quesada, A. J., Owen, R., Fernandez-Ortiz, A., Sanchez, P. L., Marin Ortuño, F., Vazquez Rodriguez, J. M., Domingo-Fernández, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2208275 · Cited by 334 · cited 1×
“This is particularly important as polypill fixed-dose combinations with statins, ACE inhibitors and aspirin have previously been shown to increase adherence and reduce cardiovascular endpoints by 24–30% compared to standard care [175].”
BackgroundGuo, L., Akahori, H., Harari, E., Smith, S. L., Polavarapu, R., Karmali, V., Otsuka, F., Gannon, R. L., Braumann, R. E., Dickinson, M. H., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci93025 · Cited by 322 · cited 1×
“In another study, semaglutide reduced the plaque content of CD163 + macrophages [108], which is associated with decreased intraplaque angiogenesis and a lower risk of plaque haemorrhage and rupture [108,157].”
BackgroundCardiovascular risk assessment in patients with diabetes
Bertoluci, M. C., & Rocha, V. Z. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0225-1 · Cited by 255 · cited 1×
“In particular, the burden of CVD will intensify, given that people with diabetes experience a two-to fourfold increased risk of developing ASCVD compared to those without [6] and that CVD accounts for two-thirds of deaths in the overweight/obese population [7].”
BackgroundMANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?
Nauck, M. A., & Meier, J. J. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0566 · Cited by 254 · cited 2×
“…through conjugation of the GLP-1 amide backbone with fatty acids, albumin, or human immunoglobulin to reduce the rate of renal elimination [42–44] Therapeutic Therapeutic GLP-1 RAs developed to date have been predominantly administered via subcutaneous injection due to poor oral…”
BackgroundLi, Y., Cao, X., Li, L.-X., Brubaker, P. L., Edlund, H., & Drucker, D. J. (2005) · Diabetes · doi:10.2337/diabetes.54.2.482 · Cited by 247 · cited 1×
“…of β cell transcription is likewise mediated via a variety of mechanisms including: increased levels of pancreatic and duodenal homeobox 1 (PDX-1) [25]; Wnt/ β -catenin-mediated transcription factor 7-like 2 (TCF7L2) expression [17]; calcineurin/nuclear factor of activated T cell (NFAT)…”
BackgroundWeight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity
Ghusn, W., De la Rosa, A., Sacoto, D., Cifuentes, L., Campos, A., Feris, F., Hurtado, M. D., & Acosta, A. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.31982 · Cited by 238 · cited 1×
“Real-world data have shown that high doses of semaglutide (1.7 mg and 2.4 mg) are associated with mean bodyweight percentage reductions of 6% after three months and 12% after six months [95].”
BackgroundInfluentialSun, F., Wu, S., Wang, J., Guo, S., Chai, S., Yang, Z., Li, L., Zhang, Y., Ji, L., & Zhan, S. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.11.008 · Cited by 232 · cited 1×
“Meta-analysis data have also associated GLP-1 RAs with modest lowering of total cholesterol, LDL-C and triglyceride levels, but direct causality between GLP-1 RA-mediated lipid-lowering effects and improved cardiovascular outcomes has not been adequately investigated [107].”
BackgroundExendin-4 Uses Irs2 Signaling to Mediate Pancreatic β Cell Growth and Function
Park, S., Dong, X., Fisher, T. L., Dunn, S., Omer, A. K., Weir, G., & White, M. F. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m508307200 · Cited by 208 · cited 1×
“PKA also activates cAMP response element-binding protein (CREB), which can, in turn, drive β cell growth by stimulating PDX-1 via insulin receptor substrate 2 (Irs2) signalling [17,31].”
BackgroundBalestrieri, M. L., Rizzo, M. R., Barbieri, M., Paolisso, P., D’Onofrio, N., Giovane, A., Siniscalchi, M., Minicucci, F., Sardu, C., D’Andrea, D., et al. (2015) · Diabetes · doi:10.2337/db14-1149 · Cited by 196 · cited 1×
“Finally, there is also evidence to support that GLP-1R agonism can stabilise plaques not only by limiting inflammation and oxidative stress but also by increasing the expression of sirtuin 6, a DNA repair deacetylase [145].”
BackgroundKrasner, N. M., Ido, Y., Ruderman, N. B., & Cacicedo, J. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097554 · Cited by 186 · cited 2×
“Liraglutide was found to confer resistance to TNF-α - and liposaccharide-induced inflammation and inhibit monocyte recruitment to the vascular endothelium by lowering VCAM-1 and E-selectin expression in cultured human aortic endothelial cells [131].”
BackgroundFrias, J. P., Hsia, S., Eyde, S., Liu, R., Ma, X., Konig, M., Kazda, C., Mather, K. J., Haupt, A., Pratt, E., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01302-8 · Cited by 184 · cited 1×
“Early trials have found benefits for both obesity [172] and diabetes [173], expanding oral GLP-1 RA choices.”
BackgroundPlamboeck, A., Veedfald, S., Deacon, C. F., Hartmann, B., Wettergren, A., Svendsen, L. B., Meisner, S., Hovendal, C., Vilsbøll, T., Knop, F. K., et al. (2013) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00035.2013 · Cited by 183 · cited 3×
“It is thought that vagal innervation is involved in the GLP-1 signalling behind appetite control, given that GLP-1 infusions increase vagal afferent firing and stimulate GLP-1R + neurons in the nodose ganglion [37].”
BackgroundInfluentialSocioeconomic Status: The Missing Link Between Obesity and Diabetes Mellitus?
Volaco, A., Cavalcanti, A. M., Filho, R. P., & Precoma, D. B. (2018) · Current Diabetes Reviews · doi:10.2174/1573399813666170621123227 · Cited by 183 · cited 1×
“It is simultaneously true that with obesity disproportionately affecting lower socioeconomic populations [163], designating weight loss as an off-label indication for GLP-1 RAs could be tantamount to financial gatekeeping, potentially further entrenching health inequities within these populations.”
BackgroundMayendraraj, A., ROSENKILDE, M. M., & Gasbjerg, L. S. (2022) · Peptides · doi:10.1016/j.peptides.2022.170749 · Cited by 183 · cited 3×
“…factor of activated T cell (NFAT) signalling [26]; increased insulin-like growth factor-1 receptor (IGF-1R) expression and membrane localisation [27]; increases in ERK1/2 due to GLP-1R-coupled β -arrestin recruitment and activation of Rap1 [17,28] and serine/threonine protein kinase B-raf [29].”
BackgroundBuse, J. B., Bain, S. C., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Pratley, R. E., Linder, M., Monk Fries, T., et al. (2020) · Diabetes Care · doi:10.2337/dc19-2251 · Cited by 175 · cited 2×
“It is also worth noting that in these analyses, changes in other metabolic variables, such as bodyweight, systolic BP and low-density lipoprotein cholesterol (LDL-C), did not reach significance for mediation [86,87].”
BackgroundMethodGlucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease
Yabut, J. M., & Drucker, D. J. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac018 · Cited by 175 · cited 1×
“Finally, GLP-1 RAs may have a role in treating nonalcoholic steatohepatitis through lowering hepatic inflammation, steatosis and fibrosis, although the mechanistic basis for this is yet to be determined [128].”
BackgroundKoska, J., Sands, M., Burciu, C., D’Souza, K. M., Raravikar, K., Liu, J., Truran, S., Franco, D. A., Schwartz, E. A., Schwenke, D. C., et al. (2015) · Diabetes · doi:10.2337/db14-0976 · Cited by 174 · cited 1×
“In addition to anti-glucolipotoxic effects on the endothelium [120], treatment in Apoe − / − mice inhibits formation of the receptor for advanced glycosylation end-products (RAGE) in the aorta and lowers serum AGE levels [121].”
BackgroundGaba, P., Gersh, B. J., Muller, J. E., Narula, J., & Stone, G. W. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00769-8 · Cited by 174 · cited 2×
“Plaques that are vulnerable to rupture have a distinctive pathological phenotype, comprising extensive inflammatory infiltration and a necrotic core with an overlying thin fibrous cap [154].”
BackgroundInflammation as a Therapeutic Target in Atherosclerosis
Nguyen, M., Fernando, S., Schwarz, N., Tan, J., Bursill, C., & Psaltis, P. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8081109 · Cited by 168 · cited 1×
“A chronically dysregulated inflammatory response underpins the progression of atherosclerosis [129].”
BackgroundSelf-citationIacobellis, G., & Villasante Fricke, A. C. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvz042 · Cited by 168 · cited 1×
“Dose-dependent reductions in EAT thickness have been observed for both semaglutide and dulaglutide in obese patients with T2DM [151].”
BackgroundKalkman, D. N., Aquino, M. B., Claessen, B. E. P. M., Baber, U., Guedeney, P., Sorrentino, S., Vogel, B., de Winter, R. J., Sweeny, J. M., Kovacic, J. C., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy633 · Cited by 166 · cited 1×
“As patients are at highest risk of recurrent ischaemic events in the early post-MI period [67], such differences in exclusion criteria can influence the cardiovascular event rates captured by different studies.”
BackgroundDissociable hindbrain GLP1R circuits for satiety and aversion
Huang, K.-P., Acosta, A. A., Ghidewon, M. Y., McKnight, A. D., Almeida, M. S., Nyema, N. T., Hanchak, N. D., Patel, N., Gbenou, Y. S. K., Adriaenssens, A. E., et al. (2024) · Nature · doi:10.1038/s41586-024-07685-6 · Cited by 166 · cited 2×
“…solitarius of the hindbrain are stimulated, and this occurs independently of aversion caused by activation of GLP-1R + neurons in the area postrema [36]. activate neurons containing pro-opiomelanocortin/cocaine-and amphetamine-stimulated transcription (POMC + /CART + ), resulting in satiety [35…”
BackgroundChen, G., Kang, W., Li, W., Chen, S., & Gao, Y. (2022) · Theranostics · doi:10.7150/thno.61747 · Cited by 163 · cited 1×
“…been predominantly administered via subcutaneous injection due to poor oral bioavailability, but the addition of sodium N-[8-(2-hydroxybenzoyl) amino caprylate (SNAC) as an absorption enhancer has circumvented this obstacle and allowed semaglutide to be given as an oral formulation [45] (Table 1).”
BackgroundHu, Y., Yang, J., Ma, X., Chen, Z., Hu, Y.-R., Zhao, J., Li, S., Qiu, Y., Lu, J., Wang, Y.-C., et al. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m044669 · Cited by 149 · cited 1×
“The GLP-1R is also involved in cholesterol efflux from foam cells mediated by the ATP-binding cassette transporter (ABCA1) [124].”
BackgroundTashiro, Y., Sato, K., Watanabe, T., Nohtomi, K., Terasaki, M., Nagashima, M., & Hirano, T. (2014) · Peptides · doi:10.1016/j.peptides.2013.12.015 · Cited by 149 · cited 1×
“GLP-1 RAs can further downregulate acetyl-CoA acetyltransferase 1 (ACAT1) expression [125] and upregulate signalling between adaptor protein phosphoty-rosine interacting with pleckstrin homology (PH) domain and leucine zipper 1 (APPL1) and adiponectin, which suppresses foam cell formation [126].”
BackgroundWorld Heart Federation Cholesterol Roadmap 2022
Ray, K. K., Ference, B. A., Séverin, T., Blom, D., Nicholls, S. J., Shiba, M. H., Almahmeed, W., Alonso, R., Daccord, M., Ezhov, M., et al. (2022) · Global Heart · doi:10.5334/gh.1154 · Cited by 146 · cited 1×
“Moderating lipid levels is crucial to reducing atherogenesis [122].”
BackgroundDai, C., Hang, Y., Shostak, A., Poffenberger, G., Hart, N., Prasad, N., Phillips, N., Levy, S. E., Greiner, D. L., Shultz, L. D., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91761 · Cited by 144 · cited 1×
“…Wnt/ β -catenin-mediated transcription factor 7-like 2 (TCF7L2) expression [17]; calcineurin/nuclear factor of activated T cell (NFAT) signalling [26]; increased insulin-like growth factor-1 receptor (IGF-1R) expression and membrane localisation [27]; increases in ERK1/2 due to GLP-1R-coupled β…”
BackgroundKatout, M., Zhu, H., Rutsky, J., Shah, P., Brook, R. D., Zhong, J., & Rajagopalan, S. (2014) · American Journal of Hypertension · doi:10.1093/ajh/hpt196 · Cited by 140 · cited 1×
“A meta-regression analysis has further clarified that reductions in systolic BP are independent of weight loss and HbA1c improvements, raising the point that GLP-1 RAs have an independent anti-hypertensive effect [103].”
BackgroundGLP-1 receptor signalling promotes β-cell glucose metabolism via mTOR-dependent HIF-1α activation
Carlessi, R., Chen, Y., Rowlands, J., Cruzat, V. F., Keane, K. N., Egan, L., Mamotte, C. D. S., Stokes, R., Gunton, J. E., de Bittencourt, P. I. H., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-02838-2 · Cited by 139 · cited 1×
“While CREB regulates the short-term pancreatic effects of GLP-1 RAs, mTOR and hypoxia-inducible factor-1 α (HIF-1 α ) signalling mediate the secondary metabolic reprogramming that alters long-term glucose processing [32].”
BackgroundGlucagon-Like Peptide 1 Receptor Activation Attenuates Platelet Aggregation and Thrombosis
Cameron-Vendrig, A., Reheman, A., Siraj, M. A., Xu, X. R., Wang, Y., Lei, X., Afroze, T., Shikatani, E., El-Mounayri, O., Noyan, H., et al. (2016) · Diabetes · doi:10.2337/db15-1141 · Cited by 137 · cited 1×
“In human cellular studies, exenatide inhibited the aggregation of platelets induced by thrombin, adenosine diphosphate (ADP) and collagen [158].”
BackgroundVinué, Á., Navarro, J., Herrero-Cervera, A., García-Cubas, M., Andrés-Blasco, I., Martínez-Hervás, S., Real, J. T., Ascaso, J. F., & González-Navarro, H. (2017) · Diabetologia · doi:10.1007/s00125-017-4330-3 · Cited by 137 · cited 1×
“…to reducing plaque size and necrotic core area in Apoe − / − Irs2 +/ − mice, lixisenatide was found to result in a greater proportion of M2-like anti-inflammatory (STAT3 + Arginase-1 + ) macrophages in aortic plaques, with fewer M1-like, pro-inflammatory (STAT1 + iNOS + ) macrophages [134].”
BackgroundSarma, S., & Palcu, P. (2022) · Obesity · doi:10.1002/oby.23563 · Cited by 133 · cited 1×
“A systematic review concurred with these epidemiological observations, concluding that bariatric surgery is superior to GLP-1 RA therapy with regard to weight loss (mean difference − 22.68 kg) and BMI reduction (mean difference − 8.18 kg/m 2 ) [99].”
ResultInfluentialEpicardial adipose tissue has a unique transcriptome modified in severe coronary artery disease
McAninch, E. A., Fonseca, T. L., Poggioli, R., Panos, A. L., Salerno, T. A., Deng, Y., Li, Y., Bianco, A. C., & Iacobellis, G. (2015) · Obesity · doi:10.1002/oby.21059 · Cited by 130 · cited 1×
“Epicardial adipose tissue (EAT), which is a store of visceral fat located between the myocardium and pericardium, has been implicated in the pathogenesis of ASCVD and has been shown to confer a pro-inflammatory milieu for the neighbouring coronary arteries [149].”
BackgroundMatikainen, N., Söderlund, S., Björnson, E., Pietiläinen, K., Hakkarainen, A., Lundbom, N., Taskinen, M., & Borén, J. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13487 · Cited by 129 · cited 1×
“Postprandial reductions in remnant cholesterol, an aggregate of very low-density lipoprotein (VLDL) and intermediate-density lipoprotein (IDL), may be mediated by liraglutide-driven reductions of ApoC III [105].”
BackgroundHonigberg, M. C., Chang, L.-S., McGuire, D. K., Plutzky, J., Aroda, V. R., & Vaduganathan, M. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.1966 · Cited by 127 · cited 2×
“The cardiovascular benefits of GLP-1 RAs are further supported by considerable preclinical and clinical research, which show that these agents exert favourable modulatory effects on atherosclerosis itself and its risk factors [10].”
BackgroundAldawsari, M., Almadani, F. A., Almuhammadi, N., Algabsani, S., Alamro, Y., & Aldhwayan, M. (2023) · Diabetes, Metabolic Syndrome and Obesity · doi:10.2147/dmso.s387116 · Cited by 115 · cited 2×
“…pro-opiomelanocortin/cocaine-and amphetamine-stimulated transcription (POMC + /CART + ), resulting in satiety [35]. beneficial effect of GLP-1 RA therapy has been attributed to the modulatory action of central appetite control, which in caloric restriction and subsequent weight loss [33].”
BackgroundHuman epicardial fat expresses glucagon-like peptide 1 and 2 receptors genes
Iacobellis, G., Camarena, V., Sant, D., & Wang, G. (2017) · Hormone and Metabolic Research · doi:10.1055/s-0043-109563 · Cited by 112 · cited 1×
“With GLP-1R expressed in EAT at much higher levels than in subcutaneous tissue [150], GLP-1 RAs may be able to target EAT for cardiovascular benefit.”
BackgroundHyperglycaemia, oxidative stress and inflammatory markers
Butkowski, E., & Jelinek, H. F. (2016) · Redox Report · doi:10.1080/13510002.2016.1215643 · Cited by 111 · cited 1×
“Diabetic hyperglycaemia fosters a pro-inflammatory and oxidative microenvironment that is conducive to the development of ASCVD and its ischaemic complications [84].”
BackgroundMiao, X., Gu, Z., Liu, P., Hu, Y., Li, L., Gong, Y., Shu, H., Liu, Y., & Li, C. (2012) · Peptides · doi:10.1016/j.peptides.2012.10.006 · Cited by 109 · cited 1×
“Similarly, GLP-1R agonism induces β cell proliferation and attenuates glucolipotoxicity through AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) signalling [24].”
BackgroundZong, P., Feng, J., Yue, Z., Li, Y., Wu, G., Sun, B., He, Y., Miller, B. A., Yu, A. S., Su, Z., et al. (2022) · Neuron · doi:10.1016/j.neuron.2022.03.021 · Cited by 109 · cited 1×
“Similarly, it can exacerbate N-methyl-D-aspartate (NMDA) receptor-related excitotoxicity and neuronal death in ischaemic stroke [138].”
BackgroundJojima, T., Uchida, K., Akimoto, K., Tomotsune, T., Yanagi, K., Iijima, T., Suzuki, K., Kasai, K., & Aso, Y. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.04.001 · Cited by 105 · cited 2×
“physiological vascular atherogenic cascade. on vascular endothelium endothelial function also evidence that GLP-1 RA-mediated eNOS/guanylyl found to delay the AMPK)-dependent arrest proliferation [118].”
BackgroundCornu, M., Modi, H., Kawamori, D., Kulkarni, R., Joffraud, M., & Thorens, B. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.091116 · Cited by 102 · cited 1×
“…factor of activated T cell (NFAT) signalling [26]; increased insulin-like growth factor-1 receptor (IGF-1R) expression and membrane localisation [27]; increases in ERK1/2 due to GLP-1R-coupled β -arrestin recruitment and activation of Rap1 [17,28] and serine/threonine protein kinase B-raf [29].”
BackgroundHelmstädter, J., Keppeler, K., Küster, L., Münzel, T., Daiber, A., & Steven, S. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15462 · Cited by 99 · cited 1×
“This may contribute to the cardiovascular bene fi ts achieved clinically This may contribute to the cardiovascular benefits achieved clinically with both synthetic GLP-1 and GLP-1 RA administration [41]. with both synthetic GLP-1 and GLP-1 RA administration [41].”
BackgroundSingh, I., Wang, L., Xia, B., Liu, J., Tahiri, A., El Ouaamari, A., Wheeler, M. B., & Pang, Z. P. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00914-3 · Cited by 98 · cited 2×
“…which indirectly suppress neurons via agouti-related peptide/neuropeptide Y (AgRP + /NPY + ) signalling, thereby reducing feelings of hunger. hypothalamus GLP-1-mediated activation of preproglucagon (Gcg + ) neurons in the arcuate nucleus regulate appetite, independently of glucose control [34].”
BackgroundRelation between gastric emptying of glucose and plasma concentrations of glucagon-like peptide-1
Wishart, J. M., Horowitz, M., Morris, H. A., Jones, K. L., & Nauck, M. A. (1998) · Peptides · doi:10.1016/s0196-9781(98)00052-7 · Cited by 95
Jones, B., McGlone, E. R., Fang, Z., Pickford, P., Corrêa, I. R., Oishi, A., Jockers, R., Inoue, A., Kumar, S., Görlitz, F., et al. (2021) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.016334 · Cited by 95 · cited 1×
“Desensitisation of the GLP-1R is prevented through regular internalisation for intracellular trafficking and recycling, mediated by G aq and β -arrestin pathways [22].”
BackgroundCastellana, M., Cignarelli, A., Brescia, F., Perrini, S., Natalicchio, A., Laviola, L., & Giorgino, F. (2019) · Scientific Reports · doi:10.1038/s41598-019-55524-w · Cited by 94 · cited 1×
“Opportunities for intensifying cardiovascular risk reduction in patients with T2DM have also been generated by combining GLP-1 RAs with other therapies, including SGLT2 inhibitors [165].”
BackgroundGlucagon-like peptide 1-related peptides increase nitric oxide effects to reduce platelet activation
Barale, C., Buracco, S., Cavalot, F. L., Frascaroli, C., Guerrasio, A., & Russo, I. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-07-0586 · Cited by 93 · cited 1×
“…liraglutide have been demonstrated to impart numerous other effects on platelet biology; these include reduction of arachidonic-induced oxidative stress, increased cGMP/protein kinase G (PKG)/vasodilator-stimulated phospho-protein (VASP) signalling and reduced PI3K/PKB and MAPK signalling [160].”
BackgroundExendin-4 Protects against Hyperglycemia-Induced Cardiomyocyte Pyroptosis via the AMPK-TXNIP Pathway
Wei, H., Bu, R., Yang, Q., Jia, J., Li, T., Wang, Q., & Chen, Y. (2019) · Journal of Diabetes Research · doi:10.1155/2019/8905917 · Cited by 91 · cited 1×
“GLP-1 RAs can additionally guard against hyperglycaemia-induced autoinflam-matory damage, inhibiting NLR family pyrin domain-containing 3 (NLRP3) inflammasome formation and thereby conferring anti-pyroptotic effects on cardiomyocytes [133].”
BackgroundHuthmacher, J. A., Meier, J. J., & Nauck, M. A. (2020) · Diabetes Care · doi:10.2337/dc20-0498 · Cited by 91
Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis
Bruen, R., Curley, S., Kajani, S., Crean, D., O'Reilly, M. E., Lucitt, M. B., Godson, C., McGillicuddy, F. C., & Belton, O. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0626-3 · Cited by 88 · cited 1×
“Similarly, liraglutide increased M2-like macrophage populations in Apoe − / − mice and increased aortic plaque expression of the anti-inflammatory mediators IL-10 and Arg-1 [135].”
BackgroundEpicardial adipose excision slows the progression of porcine coronary atherosclerosis
McKenney, M., Schultz, K. A., Boyd, J. H., Byrd, J. P., Alloosh, M., Teague, S. D., Arce‐Esquivel, A. A., Fain, J. N., Laughlin, M. H., Sacks, H. S., et al. (2014) · Journal of Cardiothoracic Surgery · doi:10.1186/1749-8090-9-2 · Cited by 85 · cited 1×
“This presents an exciting and novel therapeutic target for ASCVD prevention and treatment, as reductions in pericoronary EAT have been shown in mechanistic studies to attenuate coronary atherosclerosis [153].”
BackgroundYang, G., Lei, Y., Inoue, A., Piao, L., Hu, L., Jiang, H., Sasaki, T., Wu, H., Xu, W., Yu, C., et al. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.07.014 · Cited by 81 · cited 1×
“Exenatide was shown in a murine model of atherosclerosis to increase the collagen content of plaque and decrease MMP-9/MMP-2 activity, thereby helping to stabilise plaque [155].”
BackgroundErdogdu, Ö., Eriksson, L., Xu, H. X., Sjöholm, Å., Zhang, Q., & Nyström, T. (2013) · Journal of Molecular Endocrinology · doi:10.1530/jme-12-0166 · Cited by 80 · cited 1×
“In other work, the activation of p38 MAPK by exendin-4 was proposed to protect against lipoapoptosis [144].”
BackgroundBariatric Metabolic Surgery vs Glucagon-Like Peptide-1 Receptor Agonists and Mortality
Dicker, D., Sagy, Y. W., Ramot, N., Battat, E., Greenland, P., Arbel, R., Lavie, G., & Reges, O. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.15392 · Cited by 79 · cited 1×
“Retrospective cohort studies have found that due to the magnitude of weight loss, bariatric surgery is superior to GLP-1 RAs for reducing MACEs, although the use of second-generation GLP-1 RAs such as semaglutide was underrepresented in these studies [100,101].”
BackgroundEffects of glucagon-like peptide-1 on the differentiation and metabolism of human adipocytes
El Bekay, R., Coín‐Aragüez, L., Fernández‐García, D., Oliva‐Olivera, W., Bernal‐López, R., Clemente‐Postigo, M., Delgado‐Lista, J., Diaz‐Ruiz, A., Guzman‐Ruiz, R., Vázquez‐Martínez, R., et al. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13481 · Cited by 78 · cited 1×
“It results in downregulation of lipogenic genes and upregulation of lipolysis in human adipocytes, attenuating a systemic obesogenic state [123].”
BackgroundSvanström, H., Ueda, P., Melbye, M., Eliasson, B., Svensson, A., Franzén, S., Guðbjörnsdóttir, S., Hveem, K., Jonasson, C., & Pasternak, B. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30320-6 · Cited by 77 · cited 3×
“Svanström et al. performed a retrospective registry-based cohort analysis of 46,804 patients with T2DM in Denmark and Sweden, who were evenly distributed between the use of liraglutide and DDP-4 inhibitors [80].”
BackgroundResultInfluentialLeech, C. A., Chepurny, O. G., & Holz, G. G. (2010) · Vitamins & Hormones · doi:10.1016/b978-0-12-381517-0.00010-2 · Cited by 76
Anholm, C., Kumarathurai, P., Pedersen, L. R., Samkani, A., Walzem, R. L., Nielsen, O. W., Kristiansen, O. P., Fenger, M., Madsbad, S., Sajadieh, A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.07.007 · Cited by 75 · cited 1×
“For example, liraglutide combined with metformin lowered levels of atherogenic lipoproteins in patients with T2DM and CAD who were already taking statins [104].”
BackgroundKonig, M., Riddle, M. C., Colhoun, H. M., Branch, K. R., Atisso, C. M., Lakshmanan, M. C., Mody, R., Raha, S., & Gerstein, H. C. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01386-4 · Cited by 73
Sjöström, C. D., Lystig, T., & Lindroos, A. K. (2011) · International Journal of Obesity · doi:10.1038/ijo.2010.282 · Cited by 72 · cited 1×
“The Swedish Obese Subjects study supported this, finding that modest weight loss of 5 kg was not enough to alter CVD risk, whereas 10–44 kg weight loss in the setting of bariatric surgery was needed for significant risk factor reduction at 10-year follow-up [98].”
Malik, M. E., Falkentoft, A. C., Jensen, J., Zahir, D., Parveen, S., Alhakak, A., Andersson, C., Petrie, M. C., Sattar, N., McMurray, J. J. V., et al. (2023) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2023.100617 · Cited by 67 · cited 1×
“These can represent obstacles to patient adherence, with up to 45% of GLP-1 RA users discontinuing therapy within five years [48].”
BackgroundGLP-1 receptor agonists in diabetes for stroke prevention: a systematic review and meta-analysis
Malhotra, K., Katsanos, A. H., Lambadiari, V., Goyal, N., Palaiodimou, L., Kosmidou, M., Krogias, C., Alexandrov, A. V., & Tsivgoulis, G. (2020) · Journal of Neurology · doi:10.1007/s00415-020-09813-4 · Cited by 65 · cited 1×
“In the primary prevention setting, GLP-1 RAs have been found to reduce the incidence of both nonfatal and total strokes by around 16% [69].”
BackgroundSimental‐Mendía, L. E., Sánchez‐García, A., Linden‐Torres, E., & Simental-Mendía, M. A. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14855 · Cited by 65 · cited 1×
“Moreover, a meta-analysis of 20 randomised controlled trials revealed that, independent of fat mass changes, liraglutide significantly increased circulating adiponectin levels [148].”
BackgroundRipa, R. S., Zobel, E. H., von Scholten, B. J., Jensen, J. K., Binderup, T., Díaz, L. J., Curovic, V. R., Hansen, T. W., Rossing, P. R., & Kjær, A. (2021) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.120.012174 · Cited by 65 · cited 1×
“Conversely, the LIRAFLAME trial failed to show a significant effect of liraglutide compared to placebo on vascular inflammation as assessed by [18F]FDG PET after 26 weeks of treatment in people with T2DM [140].”
BackgroundButalia, S., Leung, A. A. C., Ghali, W. A., & Rabi, D. M. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-25 · Cited by 64 · cited 1×
“By way of reference, a 2011 systematic review of aspirin’s use for primary prevention of MACEs in patients with diabetes demonstrated an overall risk ratio of 0.91 [62].”
InfluentialYue, W., Li, Y., Ou, D., & Yang, Q. (2019) · IUBMB Life · doi:10.1002/iub.2046 · Cited by 62 · cited 1×
“…the extracellular-signal-regulated kinase 5 (ERK5) pathway, GLP-1 RAs have been shown to increase Krüppel-like factor 2 (KLF2) levels and prevent inhibition of mitogen-activated protein kinase (MAPK), which causes downstream anti-inflammatory effects, including decreased leukocyte adhesion [132].”
BackgroundVerma, S., Al‐Omran, M., Leiter, L. A., Mazer, C. D., Rasmussen, S., Saevereid, H. A., Sejersten Ripa, M., & Bonaca, M. P. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14700 · Cited by 61 · cited 1×
“For example, PAD was underrepresented in both LEADER and SUSTAIN-6, affecting only 12.7% and 14.0% of participants at baseline, respectively [73].”
BackgroundInfluentialExendin-4 Upregulates Adiponectin Level in Adipocytes via Sirt1/Foxo-1 Signaling Pathway
Wang, A., Li, T., An, P., Yan, W., Zheng, H., Wang, B., & Mu, Y. (2017) · PLOS ONE · doi:10.1371/journal.pone.0169469 · Cited by 58 · cited 1×
“To this end, GLP-1 RAs, such as exendin-4, have been shown to increase adiponectin levels via Sirt1/FoxO1 signalling [147].”
BackgroundZong, P., Feng, J., Yue, Z., Yu, A. S., Vacher, J., Jellison, E. R., Miller, B. A., Mori, Y., & Yue, L. (2022) · Nature Cardiovascular Research · doi:10.1038/s44161-022-00027-7 · Cited by 57
Jensen, J. K., Binderup, T., Grandjean, C. E., Bentsen, S., Ripa, R. S., & Kjær, A. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.03.032 · Cited by 57 · cited 1×
“Positron emission tomography (PET) imaging of rabbits identified that semaglutide reduced macrophage activation and metabolism in the aortic wall by using [ 64 Cu]Cu-DOTATATE and [18F]FDG radiotracers, respectively [139].”
MethodSudo, M., Li, Y., Hiro, T., Takayama, T., Mitsumata, M., Shiomi, M., Sugitani, M., Matsumoto, T., Hao, H., & Hirayama, A. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.06.920 · Cited by 56 · cited 1×
“In addition to murine research, a study in Ldlr − / − Watanabe heritable hyperlipi-daemic (WHHL) rabbits showed that lixisenatide promoted aortic plaque stability, with increased fibrotic tissue and reduced necrotic and calcified areas within plaques, relative to the control group [110].”
BackgroundBretón‐Romero, R., Weisbrod, R. M., Feng, B., Holbrook, M., Ko, D., Stathos, M. M., Zhang, J., Fetterman, J. L., & Hamburg, N. M. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009379 · Cited by 54 · cited 1×
“This has been demonstrated through a reduction in levels of inositol-requiring enzyme 1 α (IRE1 α ) and its downstream target c-Jun N-terminal kinase (JNK), which are markers of acute ER stress [142].”
BackgroundSukumaran, V., Tsuchimochi, H., Sonobe, T., Waddingham, M. T., Shirai, M., & Pearson, J. T. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01000-z · Cited by 54 · cited 2×
“…with There is also evidence that it causes vasodilation independent of adenosine [116]. favourable and nitric oxide synthase (NOS)-mediated vasodilation Furthermore, GLP-1 RA-mediated vasodilation can occur in states of low Nox-1/endothelin-1 and normal eNOS/guanylyl cyclase expression [117].”
BackgroundDrab, S. R. (2016) · Current Diabetes Reviews · doi:10.2174/1573399812666151223093841 · Cited by 53 · cited 2×
“GLP-1 RAs are generally not recommended in patients with any history of gastrointestinal motility disorders (e.g., gastroparesis), pancreatitis, or pancreatic cancer [49].”
BackgroundWei, J., Yang, B., Wang, R., Ye, H., Wang, Y., Wang, L., & Zhang, X. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1007980 · Cited by 50 · cited 1×
“Importantly, meta-analysis has indicated that the salutary effects on stroke outcomes were driven by reductions in ischaemic rather than haemorrhagic stroke [68].”
BackgroundGarczorz, W., Gallego-Colón, E., Kosowska, A., Kłych‐Ratuszny, A., Woźniak, M., Marcol, W., Niesner, K. J., & Francuz, T. (2017) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12317 · Cited by 47 · cited 1×
“This has been proposed to occur via activation of tissue inhibitors of metalloproteinases (TIMPs), which are natural inhibitors of MMPs [156].”
BackgroundCoronary Artery Plaque Volume and Obesity in Patients with Diabetes: The Factor-64 Study
Kwan, A. C., May, H. T., Cater, G. M., Sibley, C. T., Rosen, B. D., Lima, J. A. C., Rodriguez, K., LAPPE, D. L., Muhlestein, J. B., Anderson, J. L., et al. (2014) · Radiology · doi:10.1148/radiol.14140611 · Cited by 46 · cited 1×
“Diabetic obesity has also been independently associated with coronary plaque burden, emphasising the need to target this cardiovascular risk factor [92].”
BackgroundGiugliano, D., Bellastella, G., Longo, M., Scappaticcio, L., Maiorino, M. I., Chiodini, P., & Esposito, K. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14047 · Cited by 46 · cited 1×
“Other analyses suggest that any MACE reductions associated with HbA1c lowering are predominantly driven by reductions in nonfatal stroke [88].”
BackgroundScisciola, L., Rizzo, M. R., Cataldo, V., Fontanella, R. A., Balestrieri, M. L., D’Onofrio, N., Marfella, R., Paolisso, G., & Barbieri, M. (2020) · The FASEB Journal · doi:10.1096/fj.202000860rr · Cited by 46 · cited 1×
“Furthermore, GLP-1R agonism can reduce gene transcription of nuclear factor kappa-B (NF-κ B) and superoxide dismutase 2 (SOD2) by reversing the hyperglycaemia-induced DNA demethylation [130].”
BackgroundStenberg, E., & Näslund, E. B. (2023) · International Journal of Obesity · doi:10.1038/s41366-023-01254-z · Cited by 46 · cited 1×
“Retrospective cohort studies have found that due to the magnitude of weight loss, bariatric surgery is superior to GLP-1 RAs for reducing MACEs, although the use of second-generation GLP-1 RAs such as semaglutide was underrepresented in these studies [100,101].”
BackgroundTrümper, J., Ross, D., Jahr, H., Brendel, M. D., Göke, R., & Hörsch, D. (2005) · Diabetologia · doi:10.1007/s00125-005-1820-5 · Cited by 44 · cited 1×
“…factor of activated T cell (NFAT) signalling [26]; increased insulin-like growth factor-1 receptor (IGF-1R) expression and membrane localisation [27]; increases in ERK1/2 due to GLP-1R-coupled β -arrestin recruitment and activation of Rap1 [17,28] and serine/threonine protein kinase B-raf [29].”
BackgroundTrevisan, M., Fu, E. L., Szummer, K. E., Norhammar, A., Lundman, P., Wanner, C., Sjölander, A., Jernberg, T., & Carrero, J. J. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa004 · Cited by 44 · cited 1×
“Although only used in 2% of the cohort, GLP-1 RAs were associated with 28% lower event risk over a median follow-up of 3 years compared to standard diabetic care (95% CI [0.56, 0.92]) [81].”
InfluentialCirculating concentrations of GLP-1 are associated with coronary atherosclerosis in humans
Piotrowski, K., Becker, M., Zugwurst, J., Biller-Friedmann, I. M., Spoettl, G., Greif, M., Leber, A. W., Becker, A., Laubender, R. P., Lebherz, C., et al. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-117 · Cited by 43
Liu, Z., Zhang, M., Zhou, T., Shen, Q., & Qin, X. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.07.016 · Cited by 43 · cited 2×
“…GLP-1 RA therapy was also progression of atherosclerosis through AMP-activated protein kinase ( Through targeting AMPK/SIRT1/FoxO3a pathways, healthy vascular function is achieved by maintaining a calponin + SM22 α + VSMC phenotype [119]. of angiotensin-II-induced vascular smooth muscle cell (VSMC)”
BackgroundSanada, J., Obata, A., Obata, Y., Fushimi, Y., Shimoda, M., Kohara, K., Nakanishi, S., Mune, T., Kaku, K., & Kaneto, H. (2021) · Scientific Reports · doi:10.1038/s41598-020-80894-x · Cited by 43 · cited 2×
“Although both early and late initiation of dulaglutide reduced plaque area in Apoe − / − mice, intervention at early-but not late-stage diabetes was associated with significantly reduced macrophage infiltration into aortic root lesions [109].”
BackgroundBaviera, M., Genovese, S., Lepore, V. L., Colacioppo, P., Robusto, F., Tettamanti, M., D'Ettorre, A., Avanzini, F., Fortino, I., Nicolucci, A., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14361 · Cited by 43 · cited 1×
“…separated Italian cohorts found that GLP-1 RA use decreased rates of PAD (Lombardy cohort: HR 0.72, 95% CI [0.64–0.82]; Apulia cohort: HR 0.80, 95% CI 0.67–0.98) and lower limb complications (Lombardy cohort: HR 0.67, 95% CI [0.56–0.81]; Apulia cohort: HR 0.69, 95% CI [0.51–0.93]) [75].”
BackgroundInfluentialKalidas, P., Bikkina, P., Landicho, M. A., Parekh, S., Haas, M. J., & Mooradian, A. D. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174249 · Cited by 43 · cited 1×
“…in human coronary artery endothelial cells by downregulating the expression of glucose-regulated protein 78 (GRP78)/ATF6 and phosphorylation of protein kinase RNA-like endoplasmic reticulum kinase (PERK)/IRE1 α , and this occurred to a greater extent than with SGLT2 inhibition or metformin [143].”
BackgroundScheen, A. J. (2022) · Diabetes & Metabolism · doi:10.1016/j.diabet.2022.101325 · Cited by 43 · cited 1×
“Indeed, a recent meta-analysis suggested that GLP-1 RAs were associated with significantly lower incidence of lower limb amputations than SGLT2 inhibitors (3.54 ± 3.18 versus 4.72 ± 3.99 events per 1000 patient-years, p = 0.004) [79].”
InfluentialTRPM2 Promotes Atherosclerotic Progression in a Mouse Model of Atherosclerosis
Zhang, Y., Fan, Y., Tian, X. Y., Lei, Z., Li, X., Lo, C.-Y., Li, J., Jiang, L., & Yao, X. (2022) · Cells · doi:10.3390/cells11091423 · Cited by 42 · cited 1×
“Notably, the oxidative-stress-sensitive channel TRPM2 has also recently been shown to play a role in atherogenesis by promoting macrophage recruitment, foam cell formation and vascular inflammation within atherosclerotic plaques [136,137].”
BackgroundBenn, M., Emanuelsson, F., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2021) · Diabetologia · doi:10.1007/s00125-021-05436-0 · Cited by 41 · cited 1×
“Indeed, GLP-1 RAs and thiazolidinediones are the only two classes of diabetic drugs that have been shown to reduce stroke risk [70].”
BackgroundGlucagon-Like Peptide-1 Receptor Regulates Thromboxane-Induced Human Platelet Activation
Cahill, K. N., Amin, T., Boutaud, O., Printz, R., Newcomb, D. C., Foer, D., Hodson, D. J., Broichhagen, J., Beckman, J. A., Yu, C., et al. (2022) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2022.04.004 · Cited by 41 · cited 1×
“Meanwhile, low-dose liraglutide acutely attenuated the aggregation of platelets induced by thromboxane in a small study of nine participants with obesity and prediabetes [159].”
BackgroundXia, L., Shen, T., Dong, W., Su, F., Wang, J., Wang, Q., Niu, S., & Fang, Y. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108904 · Cited by 40 · cited 2×
“As a class, GLP-1 RAs are extremely effective at treating hyperglycaemia and lowering HbA1c levels in people with T2DM compared to other, well-established therapies, with HbA1c level reductions in the range of 0.5–1.5% compared to placebo [51].”
BackgroundInfluentialHamal, S. A., Cherukuri, L., Shaikh, K. A., Kinninger, A., Doshi, J. V., Birudaraju, D., & Budoff, M. J. (2019) · Coronary Artery Disease · doi:10.1097/mca.0000000000000830 · Cited by 39 · cited 1×
“…on Coronary Plaque Progression (STOP) trial (NCT03985384) used serial coronary computed tomography angiography (CCTA) to explore the effect of subcutaneous semaglutide on coronary plaque progression in patients with T2DM who had established ASCVD or at least one additional CVD risk factor [113].”
MethodEffect of glucagon-like peptide-1 (GLP-1) analogues on epicardial adipose tissue: A meta-analysis
Berg, G., Barchuk, M., Lobo, M., & Nogueira, J. P. (2022) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102562 · Cited by 36 · cited 1×
“This was confirmed via pooled analysis, with a mean reduction of 1.83 mm in EAT thickness following GLP-1 RA use [152].”
MethodInfluentialRecent progress of endoplasmic reticulum stress in the mechanism of atherosclerosis
Ni, L., Yang, L., & Lin, Y. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1413441 · Cited by 36 · cited 1×
“…in pancreatic β cells in diabetes, GLP-1 RAs can also alleviate the lipotoxic stress that the atherosclerotic milieu chronically places on the ER in macrophages and endothelial cells, thereby helping to mitigate the formation of necrotic cores that are characteristic of unstable plaques [141].”
BackgroundPiechocki, M., Przewłocki, T., Pieniążek, P., Trystuła, M., Podolec, J., & Kabłak-Ziembicka, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051508 · Cited by 34 · cited 1×
“Nevertheless, the currently available data do suggest that GLP-1 RAs are safe and associated with a reduction in PAD events [74].”
BackgroundLi, P., Tang, Z., Wang, L., & Feng, B. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.6978 · Cited by 32 · cited 1×
“In addition to anti-glucolipotoxic effects on the endothelium [120], treatment in Apoe − / − mice inhibits formation of the receptor for advanced glycosylation end-products (RAGE) in the aorta and lowers serum AGE levels [121].”
BackgroundPharmacokinetic and dose‐finding studies on efpeglenatide in patients with type 2 diabetes
Yoon, K., Kang, J., Kwon, S. C., TRAUTMANN, M. E., Hompesch, M., Stewart, J. A., & SORLI, C. H. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14032 · Cited by 32 · cited 2×
“…through conjugation of the GLP-1 amide backbone with fatty acids, albumin, or human immunoglobulin to reduce the rate of renal elimination [42–44] Therapeutic Therapeutic GLP-1 RAs developed to date have been predominantly administered via subcutaneous injection due to poor oral…”
BackgroundZobel, E. H., Wretlind, A., Ripa, R. S., Rotbain Curovic, V., von Scholten, B. J., Suvitaival, T., Hansen, T. W., Kjær, A., Legido-Quigley, C., & Rossing, P. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002395 · Cited by 31 · cited 1×
“Moreover, detailed lipidomic analysis revealed that liraglutide significantly lowers blood concentrations of multiple lipid species, including ceramides, phosphatidylcholines, phosphatidylethanolamines and triglycerides [106].”
BackgroundLiarakos, A. L., Tentolouris, A., Kokkinos, A. D., Eleftheriadou, I., & Tentolouris, N. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108390 · Cited by 30 · cited 1×
“With these signals of safety and possible benefit for PAD-related outcomes, GLP-1 RAs could potentially be adopted as the preferred therapy over other anti-diabetic medications in patients with concurrent T2DM and PAD [77].”
BackgroundJanić, M., Rizzo, M., Cosentino, F., Stoian, A. P., Lunder, M., Šabović, M., & Janež, A. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01226-y · Cited by 28 · cited 1×
“The ongoing SAMAS trial (NCT05147896) will examine how oral semaglutide affects parameters of ASCVD, such as arterial stiffness, carotid intima–media thickness and endothelial function, along with atherosclerotic risk factors (e.g., LDL-C, HbA1c, high-sensitivity CRP) [114].”
BackgroundPatel, V., Joharapurkar, A., Kshirsagar, S., Sutariya, B., Patel, M., Pandey, D., Patel, H., Ranvir, R., Kadam, S., Patel, D., et al. (2018) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2018.01.004 · Cited by 27 · cited 2×
“…the effects of GLP-1 RA administration alone on lipogenesis have not been studied, co-administration of GLP-1 RA with glucagon reduces lipogenesis by lowering expression of β -hydroxy β - methylglutaryl-CoA (HMG-CoA) reductase and sterol regulatory element-binding protein-1c (SBREBP-1C) [127].”
BackgroundEngineering of a GLP-1 analogue peptide/anti-PCSK9 antibody fusion for type 2 diabetes treatment
Chodorge, M., Celeste, A. J., Grimsby, J. S., Konkar, A. A., Davidsson, P., Fairman, D., Jenkinson, L., Naylor, J., White, N., Seaman, J., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-35869-4 · Cited by 24 · cited 1×
“Based on their potential synergism, a fusion therapy comprising GLP-1 RA with the potent cholesterol-lowering of proprotein convertase subtilisin/kexin type 9 inhibition (PCSK9i) is being developed, especially with an eye to patients who are intolerant or refractory to statins [166].”
BackgroundEffects of Exenatide on Coagulation and Platelet Aggregation in Patients with Type 2 Diabetes
Zhang, Y., Chen, R., Jia, Y., Chen, M., & Shuai, Z. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s312347 · Cited by 22 · cited 1×
“Furthermore, GLP-1R agonism may also inhibit platelet activation by causing platelets to have higher levels of NO and lower P-selectin and platelet activation complex-1 (PAC-1) [161].”
BackgroundIncretin treatment and atherosclerotic plaque stability: Role of adiponectin/APPL1 signaling pathway
Barbieri, M., Marfella, R., Esposito, A., Rizzo, M. R., Angellotti, E., Mauro, C., Siniscalchi, M., Chirico, F., Caiazzo, P., Furbatto, F., et al. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.10.001 · Cited by 19 · cited 1×
“GLP-1 RAs can further downregulate acetyl-CoA acetyltransferase 1 (ACAT1) expression [125] and upregulate signalling between adaptor protein phosphoty-rosine interacting with pleckstrin homology (PH) domain and leucine zipper 1 (APPL1) and adiponectin, which suppresses foam cell formation [126].”
BackgroundHwang, T. J., Franklin, J., & Kesselheim, A. S. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.705 · Cited by 16 · cited 3×
“Following the Food and Drug Administration’s (FDA) 2008 mandate that new diabetic drugs require a cardiovascular safety assessment, cardiovascular outcome trials (CVOTs) have been conducted to assess all new glucose-lowering pharmacotherapies [8].”
BackgroundInfluentialPang, B., Kim, S. J., Li, D., Ma, Z., Sun, B., Zhang, X., Wu, Z., & Chen, L. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.5136 · Cited by 16 · cited 2×
“The calcium-permeable transient receptor potential melastatin 2 (TRPM2) channel has also been implicated in GLP-1-related insulin secretion via cAMP and PKA signalling [21].”
BackgroundMannucci, E., & Silverii, G. A. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15226 · Cited by 16 · cited 1×
“…is biased towards patients with preestablished cardiovascular disease, with reductions in MACEs of 15% in people with ASCVD (OR 0.85, 95% CI [0.81–0.90], p = 0.00001) compared to 6% in people with multiple cardiovascular risk factors but no ASCVD (OR 0.94, 95% CI [0.83–1.06], p = 0.31) [60].”
BackgroundInfluentialSchäfer, Z., Mathisen, A., Thomsen, T. R., Rossing, P. R., & Kirketerp‐Møller, K. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110799 · Cited by 15 · cited 1×
“This was supported by a Danish cohort study of 309,166 patients with diabetes, which similarly showed that GLP-1 RAs were associated with a 50% lower rate of diabetes-associated amputations compared to those not on GLP-1 RA treatment (HR 0.50, 95% CI [0.54–0.74], p 0.005) [76].”
ResultInfluentialZhang, Z., Li, J., Jiang, X., Yang, L., Lei, L., Cai, D.-H., Zhang, H., & Chen, H. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2265 · Cited by 14 · cited 1×
“GLP-1 is thought to enable β islet mitogenesis via cyclin D2/Skp2 upregulation and p21/p27 downregulation, effectively reversing cell cycle arrest of pancreatic cells in hyperglycaemic states [23].”
BackgroundPharmacologically relevant drug interactions of Glucagon-like peptide-1 receptor agonists
Maideen, N. M. P. (2019) · Journal of Analytical & Pharmaceutical Research · doi:10.15406/japlr.2019.08.00311 · Cited by 14 · cited 2×
“However, besides prolonging the T max value of other medications, they do not usually affect the pharmacokinetic parameters of other drugs, such as area under curve (AUC) or maximum concentration (C max ) [46].”
BackgroundThe Polypill: A New Alternative in the Prevention and Treatment of Cardiovascular Disease
Espinosa, E. V. P., Mato, E., Guzmán, D. M. S., & Khasawneh, F. T. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13113179 · Cited by 14 · cited 1×
“The increased availability of oral options for GLP-1 RAs may also open up the possibility of their incorporation into fixed-dose polypill combinations [174].”
BackgroundFadini, G. P., Frison, V., Simioni, N., Lapolla, A., Gatti, A., Bossi, A. C., Buono, A. D., Fornengo, P., Gottardo, L., Laudato, M., et al. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012244 · Cited by 10 · cited 1×
“Alarmingly, this has also applied to specialist clinic settings for those with T2DM and established CAD, including prior MI [162].”
BackgroundGLP-1 vasodilatation in humans with coronary artery disease is not adenosine mediated
Aetesam‐ur‐Rahman, M., Giblett, J. P., Khialani, B. V., Kyranis, S. J., Clarke, S. J., Zhao, T. X., Braganza, D. M., Clarke, S., West, N. E. J., Bennett, M. R., et al. (2021) · BMC Cardiovascular Disorders · doi:10.1186/s12872-021-02030-5 · Cited by 10 · cited 2×
“Infusion of GLP-1 has been associated with There is also evidence that it causes vasodilation independent of adenosine [116]. favourable and nitric oxide synthase (NOS)-mediated vasodilation Furthermore, GLP-1 RA-mediated vasodilation can occur in states of low Nox-1/endothelin-1 and normal…”
BackgroundYing, Y.-L., Chen, Y., Jandeleit-Dahm, K. A. M., & Peter, K. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.08.006 · Cited by 2 · cited 1×
“This discrepancy could potentially be explained by the use of osmotic mini-pumps in the rabbit study, which may have artificially improved the pharmacokinetic efficacy of lixisenatide by circumventing its short half-life [111].”
Background924-P: Exploring Potential Mediators of the Cardiovascular Benefit of Dulaglutide in REWIND
Colhoun, H. M., Hasenour, C. M., Riddle, M. C., Branch, K. R., Кониг, М., Atisso, C. M., Lakshmanan, M. C., Mody, R., & Gerstein, H. C. (2020) · Diabetes · doi:10.2337/db20-924-p · Cited by 2
Cited by
Sivaprasad, S., Wong, T. Y., Gardner, T. W., Sun, J. K., & Bressler, N. M. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00646-x · Cited by 77
HOCKING, S. L., Scott, D. A., Remedios, M. L., Horowitz, M., Story, D., Greenfield, J. R., Boussioutas, A., Devereaux, B., Andrikopoulos, S., Shaw, J. E., et al. (2025) · Anaesthesia and Intensive Care · doi:10.1177/0310057x251355288 · Cited by 70
Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025)
Patel, S., & Niazi, S. K. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17081036 · Cited by 53
Body image and interest in GLP-1 weight loss medications
Markey, C. N., August, K. J., Malik, D., & Richeson, A. L. (2025) · Body Image · doi:10.1016/j.bodyim.2025.101890 · Cited by 37
Arredouani, A. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108824 · Cited by 36
Metadata
- Authors
- Le, R., Nguyen, M. T., Allahwala, M. A., Psaltis, J. P., Marathe, C. S., Marathe, J. A., & Psaltis, P. J.
- Affiliations
- Flinders University (AU)
- South Australian Health and Medical Research Institute (AU)
- The University of Adelaide (AU)
- Central Adelaide Local Health Network (AU)
- Corresponding author
- Psaltis, Peter J.
- ORCID
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2024-08-09
- Volume
- 13
- Issue
- 16
- Pages
- 4674
- ISSN
- 2077-0383 (ISSN-L)
- PMC
- PMC11355214
- OpenAlex
- W4401456648
- Semantic Scholar
- d60e5668490f218a02d74697c80196dd02a2d70d
- Cited by
- 66
- References
- 178
- Citations by year
- 2026: 32 · 2025: 31 · 2024: 3
- FWCI
- 3.87
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Heart Foundation of Australia (FLF106656)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- GLP-1 receptor agonists, cardioprotection, atherosclerotic cardiovascular disease, type 2 diabetes, obesity, weight loss, incretin-based therapy, major adverse cardiovascular events, cardiometabolic effects
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.